Objective: This systematic review was performed to evaluate the efficacy and safety of phosphodiesterase-5 inhibitors (PDE5i) in the treatment of erectile dysfunction (ED) after radiotherapy for prostate cancer (PCa). Methods: A systematic search of PubMed, Embase and the Cochrane Library was performed to identify all randomized controlled trials (RCTs). All relevant studies on the outcomes and complications of PDE5i in the treatment of ED after radiotherapy for PCa were assessed. The outcomes and complications analyzed for this study included the International Index of Erectile Function (IIEF) questionnaire, Global Efficacy Questions (GEQs), Sexual Encounter Profile (SEP) diary and side effects. The Cochrane Collaboration Review Manager software (RevMan 5.1.4) was used for statistical analysis of the outcomes and complications. Results: A total of 4 RCTs were identified from the search strategy. Compared with placebo, the trials indicated that PDE5i significantly improved the IIEF scores, with the exception of two questions (questions 6 and 13), and statistically significantly more positive answers for the GEQs and SEP diary were acquired in intervention groups. Furthermore, almost all the side effects in both groups were mild or moderate, transient and well tolerated. Except for headache, flushing and dyspepsia, all other adverse events did not differ significantly between the two groups. Conclusions: The systematic review suggested significant advantages in the efficacy and safety of PDE5i in the treatment of ED after radiotherapy for PCa. PDE5i should be considered as the first choice for the treatment of PCa patients with ED after radiotherapy.

Keywords:
Erectile dysfunction, Phosphodiesterase-5 inhibitors, Prostate cancer, Radiotherapy, Randomized controlled trial
1.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011;62:69-90.
2.
Ricardi U, Gontero P, Ciammella P, et al: Efficacy and safety of tadalafil 20 mg on demand vs. tadalafil 5 mg once-a-day in the treatment of post-radiotherapy erectile dysfunction in prostate cancer men: a randomized phase II trial. J Sex Med 2010;7:2851-2859.
3.
Harrington C, Campbell G, Wynne C, Atkinson C: Randomised, placebo-controlled, crossover trial of sildenafil citrate in the treatment of erectile dysfunction following external beam radiation treatment of prostate cancer. J Med Imaging Radiat Oncol 2010;54:224-228.
4.
Peltier A, van Velthoven R, Roumeguere T: Current management of erectile dysfunction after cancer treatment. Curr Opin Oncol 2009;21:303-309.
5.
Wespes E, Amar E, Hatzichristou D, et al: Guidelines on erectile dysfunction: an update. Eur Urol 2006;49:806-815.
6.
Mendenhall WM, Henderson RH, Indelicato DJ, Keole SR, Mendenhall NP: Erectile dysfunction after radiotherapy for prostate cancer. Am J Clin Oncol 2009;32:443-447.
7.
Bruner DW, James JL, Bryan CJ, et al: Randomized, double-blinded, placebo-controlled crossover trial of treating erectile dysfunction with sildenafil after radiotherapy and short-term androgen deprivation therapy: results of RTOG 0215. J Sex Med 2011;8:1228-1238.
8.
Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A: The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997;49:822-830.
9.
Higgins JPT, Green S (eds): Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.4 updated March 2011. The Cochrane Collaboration 2011. Available from www.cochrane-handbook.org.
10.
Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:b2535.
11.
Incrocci L, Slagter C, Slob AK, Hop WCJ: A randomized, double-blind, placebo-controlled, cross-over study to assess the efficacy of tadalafil (Cialis®) in the treatment of erectile dysfunction following three-dimensional conformal external-beam radiotherapy for prostatic carcinoma. Int J Radiat Oncol Biol Phys 2006;66:439-444.
12.
Incrocci L, Koper PCM, Hop WCJ, Slob AK: Sildenafil citrate (Viagra) and erectile dysfunction following external beam radiotherapy for prostate cancer: a randomized, double-blind, placebo-controlled, cross-over study. Int J Radiat Oncol Biol Phys 2001;51:1190-1195.
13.
Pinkawa M, Gagel B, Piroth MD, et al: Erectile dysfunction after external beam radiotherapy for prostate cancer. Eur Urol 2009;55:227-234.
14.
Ohebshalom M, Parker M, Guhring P, Mulhall JP: The efficacy of sildenafil citrate following radiation therapy for prostate cancer: temporal considerations. J Urol 2005;174:258-262.
15.
Alicikus ZA, Yamada Y, Zhang Z, et al: Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer. Cancer 2011;117:1429-1437.
16.
McVary KT: Erectile dysfunction. N Engl J Med 2007;357:2472-2481.
17.
Iacono F, Prezioso D, Somma P, Chierchia S, Galasso R, Micheli P: Histopathologically proven prevention of post-prostatectomy cavernosal fibrosis with sildenafil. Urol Int 2008;80:249-252.
18.
Nelson CJ, Weinberger MI, Balk E, Holland J, Breitbart W, Roth AJ: The chronology of distress, anxiety, and depression in older prostate cancer patients. Oncologist 2009; 14:891-899.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.